FDAsafety guidance66% confidence
Rare Disease Drug Approvals
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Anthea Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.
Supporting Context
- Therapeutic area
- Anesthesia · Injectable
- Sub-indication
- General
Related signal: FDA Grants Approval for Propofol ANDA220857 by Anthea Pharma